Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib + Venetoclax + Azacitidine in Newly Diagnosed IDH1m AML
NCT07007949Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivosidenib in acute myeloid leukemia (AML) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Complete Remission + Complete Remission with Partial Hematologic Recovery Rate at 1 year. Started Jun 2025; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07007949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007949.